AbbVie says Phase 3 AFFIRM trial shows subcutaneous Skyrizi lifts endoscopic remission in Crohn’s disease patients
Bitget2026/10/13 19:15- AbbVie released new Phase 3 AFFIRM results for subcutaneous Skyrizi in moderate-to-severe Crohn’s disease, presented at ACG 2026.
- Data showed improved intestinal healing outcomes versus placebo, supporting deeper disease control with a self-administered induction regimen.
- Findings build on previously presented week 12 results that showed Skyrizi beat placebo on clinical remission and endoscopic response.
- AbbVie is seeking FDA approval for subcutaneous induction dosing in Crohn’s disease, positioning Skyrizi for broader use earlier in treatment.
- Safety through week 24 aligned with the established profile, with no new safety signals reported.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. stock futures fluctuate by $650 billions due to news related to Jensen Huang
Nikkei Average Index gains expand to 2.78%
Surprise! Japan intervened in the forex market three times this summer, selling a record 154 trillion yen in three days
Japan has confirmed that it intervened in the foreign exchange market three times this summer, buying yen to support the exchange rate, corroborating earlier market reports. This included the first joint intervention with the United States to support the yen in nearly thirty years.
UBS CEO warns: A Democratic sweep could slow down AI capacity building, valuation concerns are "very important"
UBS CEO Ermotti stated that the U.S. midterm elections may slow down AI capacity building and that the valuations are questionable; he also warned of persistent inflation and the risk of contagion in the European bond market.
Crypto prices
More
